| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Nevadensin targets human carboxylesterase 1 (hCE1), a key enzyme involved in the hydrolysis of ester-containing drugs and xenobiotics. By inhibiting hCE1, it may affect the metabolism of various compounds and potentially enhance the efficacy of certain drugs. It also exhibits inhibitory activity against Mycobacterium tuberculosis. Its anti-inflammatory and anti-tumor effects are mediated through modulation of signaling pathways and induction of apoptosis in cancer cells. Its antioxidant activity contributes to its protective effects against oxidative stress.
|
|---|---|
| ln Vitro |
In vitro, nevadensin demonstrates selective inhibition of human carboxylesterase 1 (hCE1) with an IC50 of 2.64 μM. It exhibits inhibitory activity against Mycobacterium tuberculosis, with an MIC value of 200 μg/mL. It significantly inhibits the growth of hepatocellular carcinoma (HCC) cells by inducing cell cycle arrest and apoptosis. It induces apoptosis and DNA damage in cancer cells. It also demonstrates anti-inflammatory and antimicrobial activities in various in vitro assays.
|
| ln Vivo |
In vivo, nevadensin protects against methyleugenol-induced markers of hepatocarcinogenicity in male F344 rats. It inhibits the bioactivation of estragole, reducing the formation of DNA adducts and protecting against liver damage. Its anti-hypertensive effects have been observed in animal models. Its anti-tubercular activity has been demonstrated in vivo, though further studies are needed. Its wide range of pharmacological activities makes it a promising compound for further investigation.
|
| Enzyme Assay |
In vitro enzyme/receptor binding studies for nevadensin involve carboxylesterase 1 (hCE1) inhibition assays. Standard protocols use recombinant hCE1 enzyme incubated with a substrate such as 4-nitrophenyl acetate or a fluorescent ester in the presence of increasing concentrations of nevadensin. Enzyme activity is measured spectrophotometrically or fluorometrically, and IC50 values are calculated. For antimycobacterial activity, standard broth microdilution assays are used to determine MIC values against Mycobacterium tuberculosis.
|
| Cell Assay |
In vitro cellular assays for nevadensin involve culturing cancer cell lines (e.g., hepatocellular carcinoma, breast cancer, lung cancer) in the presence of serial dilutions of the compound. Cell viability is assessed using MTT, CellTiter-Glo, or trypan blue exclusion assays. Apoptosis is quantified by flow cytometry with Annexin V/PI staining or by measuring caspase-3/7 activity. Cell cycle analysis is performed by propidium iodide staining and flow cytometry. Anti-inflammatory activity is assessed in macrophages by measuring cytokine production (e.g., TNF-α, IL-6) upon LPS stimulation in the presence of the compound. Antimicrobial activity is assessed in bacterial cultures.
|
| Animal Protocol |
In vivo animal studies for nevadensin include models of hepatocarcinogenicity to assess its protective effects against estragole and methyleugenol-induced liver damage in male F344 rats. Anti-hypertensive effects are evaluated in spontaneously hypertensive rats. Anti-tubercular activity may be assessed in mouse models of tuberculosis infection. Anti-tumor effects could be evaluated in xenograft models using cancer cell lines. Standard protocols include dose-response assessment, histopathological examination, and biochemical analysis of biomarkers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of nevadensin are not extensively documented. As a flavonoid, it is expected to have moderate oral bioavailability, with metabolism via conjugation (glucuronidation, sulfation) and possibly by cytochrome P450 enzymes. Flavonoids are generally distributed widely in tissues and excreted in urine and bile. Its bioavailability may be influenced by food intake and gut microbiota. Detailed PK studies would be required for drug development. Its natural occurrence and traditional use suggest a favorable safety profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for nevadensin indicate that it is relatively safe, as it is a naturally occurring compound found in plants used in traditional medicine. It has shown protective effects against carcinogen-induced liver damage in animal studies. As with any bioactive compound, high doses may cause adverse effects, and standard toxicological studies would be required for drug development. Its use in traditional medicine suggests a reasonable safety profile at typical doses.
|
| References | |
| Additional Infomation |
Nevadensin is a trimethoxyflavonoid with the structure flavonoid, substituted with methoxy groups at the 6', 8', and 4' positions, and hydroxyl groups at the 5' and 7' positions, respectively. It is a plant metabolite. It is both a trimethoxyflavonoid and a dihydroxyflavonoid. Its function is related to flavonoids. It is the conjugate acid of the nivadaline-7-olate. Nevadensin has been reported to exist in the white butterfly Lysionotus pauciflorus, the toothed white butterfly Lysionotus denticulosus, and other organisms with relevant data.
Nevadensin is a naturally occurring flavonoid with a broad spectrum of pharmacological activities. It is found in various plants and has been used in traditional medicine. Its selective inhibition of human carboxylesterase 1 (hCE1) makes it a valuable tool for studying drug metabolism and interactions. Its anti-inflammatory, anti-tumor, anti-hypertensive, anti-tubercular, and antioxidant activities make it a promising lead compound for drug discovery. It is available as a research chemical for studying its biological activities and potential therapeutic applications. |
| Molecular Formula |
C18H16O7
|
|---|---|
| Molecular Weight |
344.31544
|
| Exact Mass |
344.09
|
| CAS # |
10176-66-6
|
| PubChem CID |
160921
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.387g/cm3
|
| Boiling Point |
615ºC at 760 mmHg
|
| Melting Point |
199-200℃ (chloroform methanol )
|
| Flash Point |
227ºC
|
| Vapour Pressure |
1.02E-15mmHg at 25°C
|
| Index of Refraction |
1.627
|
| LogP |
2.897
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
512
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C(=C3O2)OC)O)OC)O
|
| InChi Key |
KRFBMPVGAYGGJE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16O7/c1-22-10-6-4-9(5-7-10)12-8-11(19)13-14(20)17(23-2)15(21)18(24-3)16(13)25-12/h4-8,20-21H,1-3H3
|
| Chemical Name |
5,7-dihydroxy-6,8-dimethoxy-2-(4-methoxyphenyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~14.71 mg/mL (~42.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.26 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL | |
| 5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL | |
| 10 mM | 0.2904 mL | 1.4521 mL | 2.9043 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
